Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
Status:
Terminated
Trial end date:
2003-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Monoclonal antibodies can locate tumor cells and deliver
tumor-killing substances to them without harming normal cells. Combining chemotherapy with
monoclonal antibody therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and monoclonal
antibody therapy in treating women who have metastatic or recurrent breast cancer.